Tianjin Hemay Pharmaceutical Co., Ltd
14
1
1
9
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 75/100
21.4%
3 terminated/withdrawn out of 14 trials
75.0%
-11.5% vs industry average
14%
2 trials in Phase 3/4
0%
0 of 9 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (14)
A Phase Ⅲ Study of Hemay022 in Combination With AI In Advanced Breast Cancer
Role: lead
Study Evaluating Hemay022 in Combination With Endocrine Therapy In Subjects With ER Positive and HER2 Positive Advanced Breast Cancer
Role: lead
Multiple Ascending Dose Study to Assess Safety and Pharmacokinetics of Hemay005 In Healthy Subjects
Role: lead
Phase II Study of Hemay007 in Patients With Active Ulcerative Colitis
Role: lead
Study Evaluating Hemay020 In Subjects With Advanced Solid Cancer
Role: lead
A Phase Ⅱ Study of Hemay808 for Atopic Dermatitis Patients
Role: lead
Study Evaluating Hemay022 In Subjects With HER2-Positive Advanced Breast Cancer
Role: lead
A Phase 2 Study of Hemay007 in Patients With Rheumatoid Arthritis
Role: lead
A Phase Ⅲ Efficacy and Safety Study of Hemay005 in Subjects With Moderate to Severe Plaque Psoriasis
Role: lead
Phase II Study of Hemay005 in Patients With Active Ankylosing Spondylitis
Role: lead
A Study to Evaluate the Efficacy and Safety of Hemay005 in the Treatment of Behçet Disease
Role: lead
Efficacy and Safety Study of Hemay005 in Subjects With Moderate to Severe Plaque Psoriasis
Role: lead
A Phase I Clinical Study of Hemay808
Role: lead
PhaseⅠFirst-in-Human Study of Hemay007 in Healthy Volunteers
Role: collaborator
All 14 trials loaded